Antiverse raises funding and demonstrates therapeutic antibody identification with AI-driven drug discovery platform

Antiverse Ltd (Antiverse), a biotechnology company developing a computational antibody drug discovery platform, today announced the successful identification of functional antibody clusters targeting two G-protein-coupled receptors (GPCRs), both displaying versatile binding profiles and nanomolar affinity.

The Company also announced that it has raised $3 million funding, which will enable in-house development of the antibodies showing the highest affinity blocking function, making them ideal starting points as therapeutic assets.

The antibodies were identified using Antiverse’s proprietary computational antibody drug discovery platform, which uses machine learning to model antibody-antigen interactions and design de novo antibodies. The platform was used to identify a diverse set of binders to two structurally distinct GPCRs, and following Fluorescence-Activated Cell Sorting (FACS), 8 antibodies were identified as human GPCR binders (Figure 1). 7 of these binders were confirmed as antagonists (Figure 2), blocking GPCR activity.

This is the most comprehensive validation of our platform thus far. While identifying antibodies to GPCRs has traditionally been a complex and time-intensive process requiring expensive specialist technology and training, we have demonstrated that Antiverse’s drug discovery platform can achieve this in a fraction of the time and cost. GPCRs are commercially interesting targets associated with various indications, and these antibodies offer a path to first in vivo results and can potentially be our first assets. I would like to thank our investors, this funding will enable us to continue to develop these assets in-house with our academic collaborators.

Murat Tunaboylu, co-founder and CEO of Antiverse

GPCRs are a class of cell membrane receptors that play a crucial role in various physiological processes. Due to their link to several pathologies and diseases and the fact that approximately half of all prescription drugs target the GPCR family, they are attractive targets for drug discovery campaigns.

Diseases linked to GPCRs include diabetes, cardiovascular and psychiatric disorders. Despite these connections, very few biologic therapies have been developed for GPCRs, as they are notoriously challenging to generate antibodies against. With over 400 GPCRs linked to over 30 diseases, and only two FDA-approved antibody therapeutics existing for this family of receptors, these assets have significant potential for therapeutic applications.

Antiverse’s AI-powered methods to generate nanomolar binders against “difficult” antigens such as GPCRs in silico is a gamechanger in the antibody discovery industry, the most important innovation since the invention of phage display. We will see large savings in cost and time in the discovery and development of antibodies.

 

Peter Pack, antibody engineer and NED at Antiverse

The $3 million investment was received from new investors InnoSpark, AngelHub, Kadmos Capital and Tomorrow Scale, as well as existing investors, Tensor Ventures, Deep Science Ventures, Ed Parkinson and Development Bank of Wales (DBW).

Matt Fates, a board member at Antiverse and partner at InnoSpark commented: “We see tremendous potential in the Antiverse platform. Their combination of AI-driven antibody design with proprietary laboratory validation shows great promise in targeting historically challenging GPCRs linked to cancer and a wide variety of other conditions. We congratulate the team on their achievement in the pursuit of bringing new treatments to patients."

For more information about Antiverse’s AI-powered antibody drug discovery platform, please visit: https://www.antiverse.io/#what-we-do

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Antiverse. (2023, March 01). Antiverse raises funding and demonstrates therapeutic antibody identification with AI-driven drug discovery platform. News-Medical. Retrieved on May 19, 2024 from https://www.news-medical.net/news/20230301/Antiverse-raises-funding-and-demonstrates-therapeutic-antibody-identification-with-AI-driven-drug-discovery-platform.aspx.

  • MLA

    Antiverse. "Antiverse raises funding and demonstrates therapeutic antibody identification with AI-driven drug discovery platform". News-Medical. 19 May 2024. <https://www.news-medical.net/news/20230301/Antiverse-raises-funding-and-demonstrates-therapeutic-antibody-identification-with-AI-driven-drug-discovery-platform.aspx>.

  • Chicago

    Antiverse. "Antiverse raises funding and demonstrates therapeutic antibody identification with AI-driven drug discovery platform". News-Medical. https://www.news-medical.net/news/20230301/Antiverse-raises-funding-and-demonstrates-therapeutic-antibody-identification-with-AI-driven-drug-discovery-platform.aspx. (accessed May 19, 2024).

  • Harvard

    Antiverse. 2023. Antiverse raises funding and demonstrates therapeutic antibody identification with AI-driven drug discovery platform. News-Medical, viewed 19 May 2024, https://www.news-medical.net/news/20230301/Antiverse-raises-funding-and-demonstrates-therapeutic-antibody-identification-with-AI-driven-drug-discovery-platform.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.